JP2023524853A5 - - Google Patents

Info

Publication number
JP2023524853A5
JP2023524853A5 JP2022568380A JP2022568380A JP2023524853A5 JP 2023524853 A5 JP2023524853 A5 JP 2023524853A5 JP 2022568380 A JP2022568380 A JP 2022568380A JP 2022568380 A JP2022568380 A JP 2022568380A JP 2023524853 A5 JP2023524853 A5 JP 2023524853A5
Authority
JP
Japan
Prior art keywords
nucleic acid
ipsc
sequence
pluripotent stem
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022568380A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524853A (ja
Filing date
Publication date
Priority claimed from GBGB2006903.5A external-priority patent/GB202006903D0/en
Application filed filed Critical
Publication of JP2023524853A publication Critical patent/JP2023524853A/ja
Publication of JP2023524853A5 publication Critical patent/JP2023524853A5/ja
Pending legal-status Critical Current

Links

JP2022568380A 2020-05-11 2021-05-11 改変されたｉＰＳＣ Pending JP2023524853A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2006903.5A GB202006903D0 (en) 2020-05-11 2020-05-11 Modified iPSCs
GB2006903.5 2020-05-11
PCT/GB2021/051125 WO2021229212A1 (en) 2020-05-11 2021-05-11 Modified ipscs

Publications (2)

Publication Number Publication Date
JP2023524853A JP2023524853A (ja) 2023-06-13
JP2023524853A5 true JP2023524853A5 (enExample) 2024-04-19

Family

ID=71135035

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022568380A Pending JP2023524853A (ja) 2020-05-11 2021-05-11 改変されたｉＰＳＣ

Country Status (11)

Country Link
US (1) US20240016853A1 (enExample)
EP (1) EP4149492A1 (enExample)
JP (1) JP2023524853A (enExample)
CN (1) CN115515606A (enExample)
AU (1) AU2021271220A1 (enExample)
BR (1) BR112022022654A2 (enExample)
CA (1) CA3178047A1 (enExample)
GB (1) GB202006903D0 (enExample)
IL (1) IL298074A (enExample)
MX (1) MX2022014116A (enExample)
WO (1) WO2021229212A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2022714B1 (en) 2019-03-11 2020-09-18 Academisch Ziekenhuis Leiden Optimised RAG1 deficient SCID Gene Therapy
GB201911957D0 (en) * 2019-08-20 2019-10-02 Adaptimmune Ltd Methods of producing haemogenic progenitor cells from pluripotent stem cells
GB202111214D0 (en) * 2021-08-03 2021-09-15 Adaptimmune Ltd Modified ipscs
GB202205572D0 (en) 2022-04-14 2022-06-01 Adaptimmune Ltd Engineered T cells
AU2024269870A1 (en) * 2023-05-05 2025-11-20 Board Of Regents, The University Of Texas System Multi-receptor natural killer cells
CN118421559B (zh) * 2024-07-04 2024-09-27 成都赛济元生物医药有限公司 定向分化淋巴造血前体细胞的小分子组合、试剂盒及方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201313377D0 (en) * 2013-07-26 2013-09-11 Adaptimmune Ltd T cell receptors
US12194083B2 (en) * 2014-07-18 2025-01-14 Hiroshi Kawamoto Method for establishing pluripotent stem cells bearing genes encoding antigen specific T cell receptor
JP6715482B2 (ja) * 2014-07-18 2020-07-01 国立大学法人京都大学 多能性幹細胞から免疫細胞療法用ｔ細胞を誘導する方法
SG11201803419PA (en) * 2015-10-30 2018-05-30 The Regents Of The Universtiy Of California Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells
DK3440106T3 (da) * 2016-04-08 2021-10-04 Adaptimmune Ltd T-cellereceptorer
EP4628587A3 (en) * 2016-04-15 2026-02-25 Memorial Sloan Kettering Cancer Center Transgenic t cell and chimeric antigen receptor t cell compositions and related methods
US20190290694A1 (en) * 2016-12-21 2019-09-26 Cellectis Stably enginereed proteasome inhibitor resistant immune cells for immunotherapy
WO2018191490A1 (en) * 2017-04-13 2018-10-18 The Trustees Of The University Of Pennsylvania Use of gene editing to generate universal tcr re-directed t cells for adoptive immunotherapy
US12350312B2 (en) * 2017-09-06 2025-07-08 Fred Hutchinson Cancer Center Methods for improving adoptive cell therapy
SG11202101789SA (en) * 2018-07-26 2021-03-30 Univ Kyoto Method for generating cells into which an exogenous antigen receptor is introduced
GB201911953D0 (en) * 2019-08-20 2019-10-02 Adaptimmune Ltd T cell production fram RAG inacivated iPSCs

Similar Documents

Publication Publication Date Title
JP7451858B2 (ja) クローディン６特異的免疫受容体およびｔ細胞エピトープ
US12404492B2 (en) Methods for enhancing efficacy of therapeutic immune cells
JP2023524853A5 (enExample)
US20240024476A1 (en) CAR Cells and Polyspecific Binding Molecules for Treating Solid Tumor
US10561686B2 (en) Modified cell expansion and uses thereof
Ho et al. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction
KR102733541B1 (ko) 유전자 치료법
KR102703764B1 (ko) 클라우딘-18.2-특이적 면역수용체 및 t 세포 에피토프
EP3586852A1 (en) Modified cell expansion and uses thereof
CN110072885A (zh) TGFβ信号转换器
JP2017512054A (ja) 三官能性ｔ細胞−抗原カプラ及び方法並びにこれらの使用
AU2018396083A1 (en) Method for improving production of CAR T cells
US20210379149A1 (en) Increasing or Maintaining T-Cell Subpopulations in Adoptive T-Cell Therapy
Garber et al. Adoptive T-cell therapy for Leukemia
CN117987435A (zh) 氧依赖性嵌合抗原受体表达及其应用
JP2022506781A (ja) メソテリンを標的とする免疫療法
US20230133564A1 (en) Cd3-fusion protein and uses thereof
Dotti Control of leukemia relapse after allogeneic hematopoietic stem cell transplantation: integrating transplantation with genetically modified T cell therapies
US20240299452A1 (en) Rapamycin and Cell Therapy
CA3137808A1 (en) Cd5 specific t cell receptor cell or gene therapy
CN119143886A (zh) 靶向实体瘤的car和多特异性结合分子
HK40086170A (en) Methods for enhancing efficacy of therapeutic immune cells
KR20220095228A (ko) 암의 t 세포 치료를 위한 세포독성 효과기 기억 t 세포를 생산하는 방법
HK1248273B (en) Methods for enhancing efficacy of therapeutic immune cells
HK1248273A1 (en) Methods for enhancing efficacy of therapeutic immune cells